Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Preliminary evidence indicates famotidine might improve COVID-19 symptoms

Key clinical point: The histamine-2 receptor antagonist famotidine might improve symptoms of COVID-19 infections.

Major finding: Apart from two cases of anosmia, complete symptom resolution was reported within 14 days of initiating famotidine therapy.

Study details: Retrospective case series of 10 nonhospitalized patients.

Disclosures: The National Institutes of Health provided partial support. The investigators reported having no conflicts of interest.


Janowitz T et al. Gut. 2020 Jun 4. doi: 10.1136/gutjnl-2020-321852.